Feed aggregator

Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine

World Pharma News - Fri, 08/07/2020 - 10:00
Sanofi and GSK announced a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine.

The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's established pandemic adjuvant technology.

FDA Accepts BLA for Biogen's Alzheimer's Drug, Grants Priority Review

Biospace news - Fri, 08/07/2020 - 02:00
The FDA set a PDUFA target date of March 7, 2021 for aducanumab, Biogen said.

Octapharma Uses IVIG as Potential Treatment for COVID-19

Biospace news - Fri, 08/07/2020 - 02:00
Intravenous immunoglobulin (IVIG) could be a key to combating seriously ill COVID-19 patients who have been hospitalized due to complications from the disease, and Octapharma AG aims to find out as it assesses the plasma-based treatment in a Phase III study.

Novavax and SIPL to Develop 1 Billion COVID-19 Vaccine Doses for India, Other Countries

Biospace news - Fri, 08/07/2020 - 02:00
Novavax said the agreement will allow for the development and distribution of NVX‑CoV2373, a recombinant vaccine engineered from the genetic sequence of SARS-CoV-2, in India and in low- and middle-income countries.

White House Executive Order Aims to Boost Domestic Production of 'Essential Drugs'

Biospace news - Fri, 08/07/2020 - 02:00
In an aim to create a strong domestic supply chain, President Donald Trump signed an Executive Order on Thursday that calls for federal agencies to purchase “essential drugs” and medical supplies that are produced in the United States, rather than from abroad as is the current practice.

Biopharma Update on the Novel Coronavirus: August 7

Biospace news - Fri, 08/07/2020 - 02:00
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 7, 2020.

BioSpace Movers & Shakers, Aug. 7

Biospace news - Fri, 08/07/2020 - 02:00
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers and Shakers.

Research Roundup: Possible COVID-19 Treatment and More

Biospace news - Fri, 08/07/2020 - 02:00
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

Vigeo's Tumor Microenvironment Platform Expands Indications and Combo Therapy Possibilities

Biospace news - Fri, 08/07/2020 - 02:00
Vigeo Therapeutics is expanding indications for its tumor microenvironment (TME)-targeting oncology platform, which inhibits tumor growth by reprogramming normal cells that were recruited and coopted by a tumor.

Aerovate Therapeutics Launches with $72 Million and Repurposed Cancer Drug for PAH

Biospace news - Fri, 08/07/2020 - 02:00
Aerovate Therapeutics secured $72.6 million in Series A funding to advance trials of AV-101, an inhaled, dry powder aerosol version of Novartis’ cancer drug Gleevec (imatinib) in a repurposed effort to treat pulmonary arterial hypertension (PAH).

COVID-19: Immune system derails

World Pharma News - Thu, 08/06/2020 - 10:00
Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction - rather, the immune response is caught in a continuous loop of activation and inhibition. Experts from Charité - Universitätsmedizin Berlin, the University of Bonn, the German Center for Neurodegenerative Diseases (DZNE), the Helmholtz Centre for Infection Research (HZI) and the German Center for Infection Research (DZIF), along with colleagues from a nationwide research network, present these findings in the scientific journal Cell.

Denali and Biogen Ink Parkinson’s Pact Worth $2.125 Billion

Biospace news - Thu, 08/06/2020 - 02:00
Biogen and Denali Therapeutics inked a binding deal to co-develop and co-commercialize Denali’s small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson’s disease.

With Court Win, BMS and Pfizer Stave Off Generic Challengers to Eliquis – For Now

Biospace news - Thu, 08/06/2020 - 02:00
Investors in Bristol Myers Squibb and Pfizer are singing a happy song this morning after a federal court upheld patent claims regarding Eliquis, which blocks generic rivals from carving out a share of the market for at least six years.

Restoring Cellular Power Outages: A New Drug to Treat Mitochondrial Diseases

Biospace news - Thu, 08/06/2020 - 02:00
A small biotech company is aiming to recharge tired cells, giving mitochondrial disease patients new hope of a disease-specific treatment.

BioSpace Global Roundup, Aug. 6

Biospace news - Thu, 08/06/2020 - 02:00
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

Germany's T-knife Raises $78.4 Million to Develop CAR-T Solid Tumor Therapies

Biospace news - Thu, 08/06/2020 - 02:00
T-knife GmbH, based in Berlin, Germany, closed a €66 million (about $78.4 million, U.S.) Series A round.

Lundbeck Discontinues Phase II Schizophrenia Study Following Interim Analysis

Biospace news - Thu, 08/06/2020 - 02:00
Denmark-based Lundbeck discontinued a mid-stage proof of concept study of a schizophrenia drug following an interim analysis of data that indicated the study will not achieve statistical significance in its primary endpoint.

Tarveda’s Phase II Miniature Drug Conjugates Deliver Better Targeting, Less Toxicity than ADCs

Biospace news - Thu, 08/06/2020 - 02:00
Tarveda Therapeutics is advancing its miniature drug conjugates into Phase IIa trials, using a platform that combines the best aspects of small molecules and antibody drug conjugates while addressing their deficiencies.

Could Obesity Be Contributing to Severe Cases of COVID-19?

Biospace news - Thu, 08/06/2020 - 02:00
Although obesity is a known risk factor for death from many conditions, such as cardiovascular disease, experts are now wondering how COVID-19 may impact those who fall into this category.

AstraZeneca Signs First COVID-19 Vaccine Deal with China's Shenzhen Kangtai

Biospace news - Thu, 08/06/2020 - 02:00
AstraZeneca signed a deal with Beijing-based Shenzhen Kangtai Biological Products to manufacture AstraZeneca and the University of Oxford’s COVID-19 vaccine in mainland China.